Meeting
2015 Genitourinary Cancers Symposium
Second-line chemotherapy for metastatic urothelial cell carcinoma: Pooled analysis and construction of a prognostic model.
Authors
Samer Salah
Department of Medical Oncology, King Hussein Cance
Samer Salah , Jae-Lyun Lee , Antonio Rozzi , Hiroshi Kitamura , Kazumasa Matsumoto , Sandy Srinivas , Rafael Morales , Joan Carles , Rami Al-Wardat , Mohammad Maakoseh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 309)
DOI
10.1200/jco.2015.33.7_suppl.309
Abstract #
309
Poster Bd #
E20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.
First Author: Timothy J Brown
Poster
2014 ASCO Annual Meeting
Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.
First Author: Bertrand Brieau
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC).
First Author: Nathaniel R. Wilson
Poster
2021 ASCO Annual Meeting
Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.
First Author: Joaquim Bellmunt